FDA approved Orserdu (elacestrant) for postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
The NRG Oncology Group Chairs created the position of associate group chair and selected Charles E. Geyer to fill the position, effective immediately. He will serve alongside the three NRG Oncology group chairs, Quynh-Thu Le, Robert Mannel, and Norman Wolmark.
